[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cyclin-dependent-kinase-4-inhibitor-b":3},{"name":4,"total":5,"recruiting":5,"trials":6},"Cyclin-Dependent Kinase 4 Inhibitor B",3,[7,15,21],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05843253","Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant",[11],"Phase 2","RECRUITING","2026-08-26T02:19:31.671303Z","2026-05-05T02:43:29.388169Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT04040205","Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration",[11],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:28.417090Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT06577987","Safety\u002FEfficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies",[25],"Phase 1","2026-08-26T02:19:00.742020Z","2026-05-05T02:43:27.665400Z"]